Abstract | BACKGROUND: The clinical outcome of refractory head and neck (H&N) cancer patients remains poor despite novel treatment strategies. In this pilot study the efficacy of intratumoral injection of 32-P chromic phosphate in 14 patiehts with refractory H&N carcinomas was investigated in terms of response rates and overall survival. PATIENTS AND METHODS: Fourteen patients (median age: 59 years) with either cytostatic drug-resistant tumours or tumours known to be primarily chemotherapy-resistant were entered into the study. After sonographic determination of the tumour volume, 32-P chromic phosphate (74-444 MBq) was injected into the central part of the tumour under sonographic guidance. Follow-up investigations included serial scintigraphy, sonographic examinations and hematological studies. RESULTS: Injection of 32-P chromic phosphate into refractory H&N tumours resulted in remarkable regression. The median survival of all patients was 7.8 months (range: 4-16). Eight patients exhibited a partial response, while 6 patients did not respond to the treatment. In 3 patients thrombocytopenia (grade I/II) was observed, but no other significant side-effects were apparent. Significant pathological and anatomical changes within the tumour tissue were demonstrated. In all cases examined, formation of a cyst within the area of central activity, surrounded by a centrifugal necrotic ring and a marginal fibrotic structure, was found. CONCLUSION: A lack of persistent systematic or local side-effects, as well as noteworthy efficacy, are properties of this novel regional treatment modality with 32-P chromic phosphate. This modality deserves consideration for further clinical trials.
|
Authors | Kyrus A Alimi, Nosrat Firusian, Wolfram Dempke |
Journal | Anticancer research
(Anticancer Res)
2007 Jul-Aug
Vol. 27
Issue 4C
Pg. 2997-3000
ISSN: 0250-7005 [Print] Greece |
PMID | 17695485
(Publication Type: Journal Article)
|
Chemical References |
- Chromium Compounds
- Phosphates
- Radiopharmaceuticals
- chromic phosphate, 32P-labeled
|
Topics |
- Adult
- Aged
- Chromium Compounds
(administration & dosage, adverse effects, pharmacokinetics)
- Head and Neck Neoplasms
(metabolism, pathology, radiotherapy)
- Humans
- Injections, Intralesional
- Middle Aged
- Phosphates
(administration & dosage, adverse effects, pharmacokinetics)
- Radiopharmaceuticals
(administration & dosage, adverse effects, pharmacokinetics)
- Survival Rate
|